- $513.89m
- $417.99m
- $85.23m
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Q2 revenue rises, beats estimates
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Q1 revenue beats on Hepzato growth
Brief: Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology
Delcath Q4 revenue rises 37%, beats estimates
Brief: Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Delcath Systems Announces Preliminary Fourth Quarter And Full Year 2025 Financial Results
Brief: Delcath Systems Board Of Directors Authorizes $25 Million Share Repurchase Program
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cancer therapy developer Delcath Q3 revenue misses estimates
Brief: Delcath Systems Announces Investigator-Initiated Chopin Phase 2 Trial Presentation At ESMO 2025 Congress
Brief: Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Interventional oncology firm Delcath's Q2 revenue beats estimates
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Delcath Systems, Seagate, Perpetua Resources